Grimes & Company Inc. purchased a new stake in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report) during the fourth quarter, Holdings Channel reports. The institutional investor purchased 14,715 shares of the company’s stock, valued at approximately $967,000.
A number of other hedge funds also recently bought and sold shares of IHE. Rockport Wealth LLC acquired a new stake in iShares U.S. Pharmaceuticals ETF in the 2nd quarter valued at about $12,091,000. Pallas Capital Advisors LLC acquired a new stake in shares of iShares U.S. Pharmaceuticals ETF during the 4th quarter worth about $3,829,000. Flow Traders U.S. LLC acquired a new stake in shares of iShares U.S. Pharmaceuticals ETF during the 3rd quarter worth about $839,000. Marshall Wace LLP acquired a new stake in shares of iShares U.S. Pharmaceuticals ETF during the 2nd quarter worth about $422,000. Finally, Thrivent Financial for Lutherans raised its position in shares of iShares U.S. Pharmaceuticals ETF by 23.6% during the 3rd quarter. Thrivent Financial for Lutherans now owns 32,509 shares of the company’s stock worth $2,295,000 after acquiring an additional 6,214 shares in the last quarter.
iShares U.S. Pharmaceuticals ETF Stock Performance
Shares of NYSEARCA IHE opened at $68.00 on Friday. iShares U.S. Pharmaceuticals ETF has a fifty-two week low of $62.67 and a fifty-two week high of $72.94. The firm has a market capitalization of $686.80 million, a PE ratio of 6.49 and a beta of 0.58. The stock’s 50-day simple moving average is $67.06 and its 200-day simple moving average is $69.01.
About iShares U.S. Pharmaceuticals ETF
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
See Also
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- Why Are Stock Sectors Important to Successful Investing?
- Bloom Energy: Powering the Future With Decentralized Energy
- What is a Special Dividend?
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- Breakout Stocks: What They Are and How to Identify Them
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Want to see what other hedge funds are holding IHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report).
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
